What is HC Wainwright's Estimate for SPRO Q3 Earnings?

Key Points

• HC Wainwright expects Spero Therapeutics to report a Q3 2026 loss of $0.14 per share and maintains a “Buy” rating with a $6.00 price target. The firm also forecasts losses of $0.14 per share in Q4 2026, $0.58 for FY2026, and $0.88 for FY2027.
• Analyst sentiment is mixed, with one Buy rating and three Holds, resulting in a consensus “Hold” rating and a $6.00 average price target.
• SPRO was trading at $1.14, near its 12-month low of $1.08, while institutional investors—including Alphabet and BlackRock—recently initiated positions; institutions own 25.6% of the company.

Spero Therapeutics, Inc. (NASDAQ:SPRO - Free Report) - Research analysts at HC Wainwright issued their Q3 2026 EPS estimates for Spero Therapeutics in a note issued to investors on Monday, September 14th. HC Wainwright analyst R. Selvaraju anticipates that the company will earn ($0.14) per share for the quarter. HC Wainwright has a "Buy" rating and a $6.00 price target on the stock. HC Wainwright also issued estimates for Spero Therapeutics' Q4 2026 earnings at ($0.14) EPS, FY2026 earnings at ($0.58) EPS and FY2027 earnings at ($0.88) EPS.

Other analysts also recently issued reports about the stock. Weiss Ratings raised shares of Spero Therapeutics from a "sell (d-)" rating to a "hold (c-)" rating in a research report on Wednesday, August 12th. Compass Point upgraded shares of Spero Therapeutics to a "neutral" rating in a report on Monday. One investment analyst has rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, Spero Therapeutics currently has a consensus rating of "Hold" and an average target price of $6.00.

Spero Therapeutics Trading Up 0.9%

SPRO opened at $1.14 on Tuesday. The company has a market cap of $66.39 million, a price-to-earnings ratio of 10.36 and a beta of 1.49. The stock has a fifty day simple moving average of $1.34 and a two-hundred day simple moving average of $2.11. Spero Therapeutics has a 12-month low of $1.08 and a 12-month high of $3.08.

Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%.

Hedge Funds Weigh In On Spero Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Alphabet Inc. bought a new position in Spero Therapeutics in the 2nd quarter worth about $1,967,000. BlackRock Inc. bought a new stake in Spero Therapeutics during the 2nd quarter valued at about $1,314,000. GSA Capital Partners LLP purchased a new position in Spero Therapeutics in the second quarter worth about $632,000. Intrepid Family Office LLC raised its holdings in Spero Therapeutics by 50.0% in the fourth quarter. Intrepid Family Office LLC now owns 165,000 shares of the company's stock worth $384,000 after buying an additional 55,000 shares during the last quarter. Finally, Global Retirement Partners LLC bought a new position in shares of Spero Therapeutics in the second quarter worth approximately $55,000. 25.60% of the stock is currently owned by institutional investors.

Spero Therapeutics Company Profile

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company's lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.